Stock News•2 weeks ago
Can Eliquis Cushion Bristol Myers' Legacy Portfolio Erosion?
Bristol Myers Squibb's 2026 revenue outlook brightened after stronger Eliquis sales, which could cushion legacy portfolio erosion from generic pressure.
MarketLens
Why is Barclays Bullish on Bristol-Myers Squibb (BMY) Now
6 months ago
SHARE THIS ON:
Exclusive Content for Pro Members
Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.
SHARE THIS ON:
Related Articles
Category
You may also like
Stock News•1 months ago
Bristol Myers Squibb Isn't Nearly as Cheap as It Looks -- Here's the 1 Thing That Could Change That
Bristol Myers Squibb's apparent value from its P/E and 4% yield masks a material patent cliff, which investors should monitor. The patent expirations could pressure earnings unless new products offset...
Stock News•1 months ago
Bristol Myers Squibb (BMY) Reports Next Week: Wall Street Expects Earnings Growth
Bristol Myers Squibb (BMY) reports earnings next week, with Wall Street expecting growth. The company has key ingredients for a likely beat.
Breaking News
View All →Featured Articles
Top Headlines
Stock News•45 minutes ago
Prediction: Sept. 10 Will Be a Big Day for Nvidia Shareholders.
Stock News•2 hours ago
QQQ vs QQQM: Same Index, Same Stocks, Different Fee – and the Math Says One Leaves You Thousands Richer
Stock News•2 hours ago
Qualcomm CFO on Amazon AI Deal, Data Center Strategy
Stock News•3 hours ago
Meta Targets Mass Market Automation With New Muse AI Agent
Stock News•3 hours ago